REGN

Regeneron Pharmaceuticals, Inc. (REGN) | Rumor.io

Regeneron Pharmaceuticals

REGN

Attention (50-day avg)0%

Attention rank (50-day avg)#827

Bullish sentiment (50-day avg)87%

Price to earnings ratio19.5

Market capitalization77.4B

Earnings per share38.6

Dividend yield (TTM)0.5%

Revenue (annual)14.3B

Net income (annual)4.5B

Social

What share of all stock conversation is about REGN?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% -0.01	0% +0	0% 0	0% -0.01

Sep 28

$REGN's Eylea faces competition from Kodiak Sciences' zenkuda, an anti-VEGF antibody, which matched Eylea's Phase 3 trial results.
Wellington Management Group LLP reduced its $REGN position by 30.9% in June 2026, leaving them with 1,270,087 shares worth an estimated $791.95 million.
Kodiak Sciences' stock surged 166% after announcing Phase 3 trial results matching $REGN's Eylea, with one candidate, zenkuda, to be submitted to regulators.

Generated by AI

Sentiment

Of the messages about REGN that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	33.33% -66.67	91.14% +5.29	87.18% +11.3
Bearish	—	66.67% +66.67	8.86% -5.29	12.82% -11.3

Bullish· Mar 2

Regeneron Pharmaceuticals, Inc. ($REGN) has a promising CHMP nod for Dupixent expansion, with a positive recommendation for treating children aged 2 to 11 with chronic spontaneous urticaria.
Analysts are optimistic about $REGN's Q1 earnings, with Wall St expecting 9.16 EPS, and RBC Capital maintaining a Sector Perform rating with a raised price target to $765.
$REGN has shown significant growth potential, with a similar stock recommendation up 40% since mention, and the author expecting to catch the current move.

Bearish· May 18

Regeneron Pharmaceuticals' ($REGN) Fianlimab Phase 3 melanoma trial failed to beat Keytruda statistically, leading to a downgrade by Citi with a reduced target price from $900 to $700.
The company's poorly run nature has been criticized by many in the industry, with some advising investors to exit the stock while they can.
Regeneron's stock is in a bearish technical structure, trading below both major moving averages with continued negative momentum, according to an AI-driven analysis.

Generated by AI

Topics

Of the messages about REGN that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	71.43%	93.62%	47.64%	27.87%
Technical Analysis	0%	4.96%	2.09%	5.81%
Macro	0%	0%	24.61%	30.94%
Analysts	28.57%	1.42%	25.13%	31.37%
Controversies	0%	0%	0%	1.52%
Earnings	0%	0%	0.52%	2.48%

Earnings· Jan 30

Regeneron Pharmaceuticals (REGN) reported Q4 2025 earnings, with adjusted EPS of $11.44, beating estimates by $0.92, and revenue of $3.9B, surpassing expectations.
The company's Dupixent sales with Sanofi rose 34% in Q4 to $4.9B, while EYLEA HD sales in the US jumped 66% to $506M, but total EYLEA sales declined due to competition.
Regeneron's Q4 results were driven by strong collaboration revenue growth and continued momentum from Dupixent and EYLEA HD, but the company's core Eylea sales weakness persists, warranting caution for investors.

Analysts· Jan 7

BofA Securities has upgraded Regeneron Pharmaceuticals ($REGN) to Buy from Underperform and raised the price target to $860 from $627.
The upgrade is driven by improved outlooks for Eylea HD, Dupixent, and potential pipeline updates, including a Phase 3 melanoma readout in 2026.
Analysts are more bullish on Eylea HD's potential in light of multiple label updates, and see further upside from Dupixent and the company's pipeline in 2026.

Announcements· May 18

Regeneron Pharmaceuticals, Inc. ($REGN) has entered a $2.3B strategic collaboration with Parabilis Medicines to develop novel antibody-Helicon conjugates across multiple therapeutic areas.
The deal includes a $125M upfront payment and up to $2.2B in potential milestones, with a focus on advancing Parabilis' Helicon-based take on antibody-drug conjugates (ADCs).
Regeneron's stock price dropped 11.8% after a Phase 3 trial for its LAG-3 inhibitor combo failed to meet its primary goal in a late-stage melanoma study.

Controversies· Jun 24

Federal prosecutors allege that Regeneron Pharmaceuticals used a charity to pay kickbacks to Medicare patients for its eye drug Eylea.
Regeneron management, including the company's commercial chief, allegedly lied to auditors about the information the company was getting from the foundation about Eylea.
The U.S. Justice Department has sued Regeneron, accusing it of using a charity to pay kickbacks for its expensive macular degeneration drug Eylea.

Macro· Oct 8

The US government's potential use of taxpayer funds for Regeneron Pharmaceuticals' ($REGN) COVID-19 antibody treatment may be linked to the 2020 elections.
Regeneron Pharmaceuticals ($REGN) needs to maintain a good relationship with the FDA to ensure the success of its products.
The US president has threatened China, implying that it will pay a price for its actions, without directly mentioning $REGN or its products.

Technical Analysis· Oct 5

$REGN has broken above its 50-day moving average, indicating a possible accumulation day.
The stock's monthly chart shows a bull flag and inside month brewing, suggesting a potential trend continuation.
$REGN's RSI has crossed above 50, indicating a possible sign of strength, and the stock has also shown a breakout above the 100 SMA, which could lead to a big move.

Generated by AI

Community

Of the messages about REGN, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	96%	41.77%	46.2%	50.99%
Newcomers	4%	58.23%	53.8%	49.01%

Regulars· Jul 30

Revenue for Regeneron Pharmaceuticals ($REGN) increased 17% YoY to $4.29B, beating estimates of $3.82B, driven by strong sales of Dupixent and EYLEA HD.
Dupixent global net sales rose 38% YoY to $6.0B, with EYLEA HD U.S. net sales increasing 52% YoY to a new all-time high of $596M.
Regeneron's adjusted EPS of $14.29 beat estimates of $10.26, with a 11% YoY increase, while GAAP EPS was $12.23, a 5% YoY decrease.

Newcomers· Jul 14

The newcomer is focused on the high forward multiple of Regeneron Pharmaceuticals, suggesting that it may be overvalued.
They are concerned about the retail sentiment warning people away from the stock, which they see as an unusual risk assessment in the market.
The newcomer is trying to identify the "trap" in the stock, implying that they believe there is a potential problem or issue with Regeneron Pharmaceuticals that needs to be addressed.

Generated by AI

News

Regeneron stands out as top value pick among large-cap pharma stocks

16h agoInvesting.com

RBC Capital reiterates Regeneron stock rating on JV survey results

21h agoInvesting.com

Why Did Regeneron Pharmaceuticals (REGN) Stock Drop Today?

Regeneron Pharmaceuticals (REGN) is back in focus after Biohaven entered a new clinical supply agreement to pair BHV-1530 with Regeneron’s cancer drug Libtayo in patients with solid tumors, with enrollment in the combination cohort already underway. Despite today’s pullback, with the share price down 4.54% over the past day to US$752.25 and weaker recent momentum, Regeneron Pharmaceuticals still carries a 90 day share price return of 20.64% and a 1 year total shareholder return of 34.84%...

1d agoYahoo Finance

What Does Regeneron Pharmaceuticals (REGN) Need To Prove In Eye Disease Now?

Regeneron Pharmaceuticals (NasdaqGS: REGN) faces fresh pressure after Kodiak Sciences reported new Phase 3 data on its eye drugs. Kodiak said Zenkuda and tabirafusp alfa tedromer matched Eylea on primary Phase 3 endpoints for macular degeneration treatment. The trial reported similar vision outcomes with Kodiak's candidates given roughly every six months versus Eylea's current eight week dosing interval. This comparison between Eylea and Kodiak's longer interval injections is only one piece...

1d agoYahoo Finance

New Eye Treatment Boosts Kodiak Into Ranks of Resurgent Biotechs

Its latest study suggested its drug candidates improved eyesight for patients with wet macular degeneration as much as the leading treatment.

1d agoYahoo Finance

KOD Stock Cracks September’s Top 5 Biotech Gainers On Eye Drug Win — But ‘Pharma Bro’ Shkreli Says It ‘Still Sucks’

Martin Shkreli, who said he was short KOD before the readout, questioned Zenkuda’s edge over Eylea and dismissed the added IL-6 targeting in KSI-501.

1d agoYahoo Finance

Also Discussed

Investors talking about REGN also mention

#	Name	Attention
1	Sanofi ADRSNY	0%-0.01
2	Biogen IncBIIB	0%-0.01
3	Vertex Pharmaceuticals Incorporated Common StockVRTX	0%-0.01
4	Gilead Sciences, Inc.GILD	0%-0.04
5	Alnylam Pharmaceuticals, Inc.ALNY	0%0
6	Amgen Inc.AMGN	0.01%+0
7	BioMarin Pharmaceutical IncBMRN	0%+0
8	Merck & Co., Inc.MRK	0.01%-0.06
9	Novartis AG Sponsored ADRNVS	0%-0.01
10	Incyte Corp.INCY	0%new

Regeneron Pharmaceuticals, Inc.

Healthcare
Biotechnology

Regeneron Pharmaceuticals, Inc. is a biotechnology company that discovers, develops, manufactures, and commercializes medicines for people with serious diseases. Its portfolio spans treatments in eye care, immunology, oncology, cardiovascular and metabolic disease, infectious disease, hematology, and rare disorders. The company is known for combining laboratory research, clinical development, and in-house manufacturing to advance biologic therapies and antibody-based medicines. Regeneron also works on product candidates across multiple therapeutic areas, supporting a broad drug pipeline alongside its marketed medicines. Regeneron Pharmaceuticals, Inc. plays an important role in the healthcare market through its focus on specialty therapies designed for complex and often chronic medical conditions.

Website

Location

777 Old Saw Mill River Road

Tarrytown, NY, 10591-6707

United States

Social

What share of all stock conversation is about REGN?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% -0.01	0% +0	0% 0	0% -0.01

Sep 28

$REGN's Eylea faces competition from Kodiak Sciences' zenkuda, an anti-VEGF antibody, which matched Eylea's Phase 3 trial results.
Wellington Management Group LLP reduced its $REGN position by 30.9% in June 2026, leaving them with 1,270,087 shares worth an estimated $791.95 million.
Kodiak Sciences' stock surged 166% after announcing Phase 3 trial results matching $REGN's Eylea, with one candidate, zenkuda, to be submitted to regulators.

Generated by AI

Sentiment

Of the messages about REGN that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	33.33% -66.67	91.14% +5.29	87.18% +11.3
Bearish	—	66.67% +66.67	8.86% -5.29	12.82% -11.3

Bullish· Mar 2

Regeneron Pharmaceuticals, Inc. ($REGN) has a promising CHMP nod for Dupixent expansion, with a positive recommendation for treating children aged 2 to 11 with chronic spontaneous urticaria.
Analysts are optimistic about $REGN's Q1 earnings, with Wall St expecting 9.16 EPS, and RBC Capital maintaining a Sector Perform rating with a raised price target to $765.
$REGN has shown significant growth potential, with a similar stock recommendation up 40% since mention, and the author expecting to catch the current move.

Bearish· May 18

Regeneron Pharmaceuticals' ($REGN) Fianlimab Phase 3 melanoma trial failed to beat Keytruda statistically, leading to a downgrade by Citi with a reduced target price from $900 to $700.
The company's poorly run nature has been criticized by many in the industry, with some advising investors to exit the stock while they can.
Regeneron's stock is in a bearish technical structure, trading below both major moving averages with continued negative momentum, according to an AI-driven analysis.

Generated by AI

Topics

Of the messages about REGN that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	71.43%	93.62%	47.64%	27.87%
Technical Analysis	0%	4.96%	2.09%	5.81%
Macro	0%	0%	24.61%	30.94%
Analysts	28.57%	1.42%	25.13%	31.37%
Controversies	0%	0%	0%	1.52%
Earnings	0%	0%	0.52%	2.48%

Earnings· Jan 30

Regeneron Pharmaceuticals (REGN) reported Q4 2025 earnings, with adjusted EPS of $11.44, beating estimates by $0.92, and revenue of $3.9B, surpassing expectations.
The company's Dupixent sales with Sanofi rose 34% in Q4 to $4.9B, while EYLEA HD sales in the US jumped 66% to $506M, but total EYLEA sales declined due to competition.
Regeneron's Q4 results were driven by strong collaboration revenue growth and continued momentum from Dupixent and EYLEA HD, but the company's core Eylea sales weakness persists, warranting caution for investors.

Analysts· Jan 7

BofA Securities has upgraded Regeneron Pharmaceuticals ($REGN) to Buy from Underperform and raised the price target to $860 from $627.
The upgrade is driven by improved outlooks for Eylea HD, Dupixent, and potential pipeline updates, including a Phase 3 melanoma readout in 2026.
Analysts are more bullish on Eylea HD's potential in light of multiple label updates, and see further upside from Dupixent and the company's pipeline in 2026.

Announcements· May 18

Regeneron Pharmaceuticals, Inc. ($REGN) has entered a $2.3B strategic collaboration with Parabilis Medicines to develop novel antibody-Helicon conjugates across multiple therapeutic areas.
The deal includes a $125M upfront payment and up to $2.2B in potential milestones, with a focus on advancing Parabilis' Helicon-based take on antibody-drug conjugates (ADCs).
Regeneron's stock price dropped 11.8% after a Phase 3 trial for its LAG-3 inhibitor combo failed to meet its primary goal in a late-stage melanoma study.

Controversies· Jun 24

Federal prosecutors allege that Regeneron Pharmaceuticals used a charity to pay kickbacks to Medicare patients for its eye drug Eylea.
Regeneron management, including the company's commercial chief, allegedly lied to auditors about the information the company was getting from the foundation about Eylea.
The U.S. Justice Department has sued Regeneron, accusing it of using a charity to pay kickbacks for its expensive macular degeneration drug Eylea.

Macro· Oct 8

The US government's potential use of taxpayer funds for Regeneron Pharmaceuticals' ($REGN) COVID-19 antibody treatment may be linked to the 2020 elections.
Regeneron Pharmaceuticals ($REGN) needs to maintain a good relationship with the FDA to ensure the success of its products.
The US president has threatened China, implying that it will pay a price for its actions, without directly mentioning $REGN or its products.

Technical Analysis· Oct 5

$REGN has broken above its 50-day moving average, indicating a possible accumulation day.
The stock's monthly chart shows a bull flag and inside month brewing, suggesting a potential trend continuation.
$REGN's RSI has crossed above 50, indicating a possible sign of strength, and the stock has also shown a breakout above the 100 SMA, which could lead to a big move.

Generated by AI

Community

Of the messages about REGN, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	96%	41.77%	46.2%	50.99%
Newcomers	4%	58.23%	53.8%	49.01%

Regulars· Jul 30

Revenue for Regeneron Pharmaceuticals ($REGN) increased 17% YoY to $4.29B, beating estimates of $3.82B, driven by strong sales of Dupixent and EYLEA HD.
Dupixent global net sales rose 38% YoY to $6.0B, with EYLEA HD U.S. net sales increasing 52% YoY to a new all-time high of $596M.
Regeneron's adjusted EPS of $14.29 beat estimates of $10.26, with a 11% YoY increase, while GAAP EPS was $12.23, a 5% YoY decrease.

Newcomers· Jul 14

The newcomer is focused on the high forward multiple of Regeneron Pharmaceuticals, suggesting that it may be overvalued.
They are concerned about the retail sentiment warning people away from the stock, which they see as an unusual risk assessment in the market.
The newcomer is trying to identify the "trap" in the stock, implying that they believe there is a potential problem or issue with Regeneron Pharmaceuticals that needs to be addressed.

Generated by AI

Regeneron Pharmaceuticals

Social

Sep 28

Bullish· Mar 2

Bearish· May 18

Earnings· Jan 30

Analysts· Jan 7

Announcements· May 18

Controversies· Jun 24

Macro· Oct 8

Technical Analysis· Oct 5

Regulars· Jul 30

Newcomers· Jul 14

Regeneron stands out as top value pick among large-cap pharma stocks

RBC Capital reiterates Regeneron stock rating on JV survey results

Why Did Regeneron Pharmaceuticals (REGN) Stock Drop Today?

What Does Regeneron Pharmaceuticals (REGN) Need To Prove In Eye Disease Now?

New Eye Treatment Boosts Kodiak Into Ranks of Resurgent Biotechs

KOD Stock Cracks September’s Top 5 Biotech Gainers On Eye Drug Win — But ‘Pharma Bro’ Shkreli Says It ‘Still Sucks’

Also Discussed

Regeneron Pharmaceuticals, Inc.

Company Information

Location

Regeneron stands out as top value pick among large-cap pharma stocks

RBC Capital reiterates Regeneron stock rating on JV survey results

Why Did Regeneron Pharmaceuticals (REGN) Stock Drop Today?

What Does Regeneron Pharmaceuticals (REGN) Need To Prove In Eye Disease Now?

New Eye Treatment Boosts Kodiak Into Ranks of Resurgent Biotechs

KOD Stock Cracks September’s Top 5 Biotech Gainers On Eye Drug Win — But ‘Pharma Bro’ Shkreli Says It ‘Still Sucks’

Also Discussed

Social

Sep 28

Bullish· Mar 2

Bearish· May 18

Earnings· Jan 30

Analysts· Jan 7

Announcements· May 18

Controversies· Jun 24

Macro· Oct 8

Technical Analysis· Oct 5

Regulars· Jul 30

Newcomers· Jul 14